Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.38 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514936 | 0.89 | MCL1 (0.53) | MCL1ALDH1A1 | |
| SCHEMBL8514743 | 0.88 | MCL1 (0.43) | MCL1PPARAPTGS2HIF1A | |
| SCHEMBL8513539 | 0.86 | HIF1A (0.39) | MCL1PTGS2HIF1A | |
| SCHEMBL8513874 | 0.86 | HIF1A (0.39) | MCL1PTGS2S1PR2HIF1A | |
| SCHEMBL8515249 | 0.85 | LPAR1 (0.41) | MCL1PPARAPTGS2LPAR1HIF1A | |
| SCHEMBL8515015 | 0.83 | PTGS2 (0.40) | MCL1PTGS2HIF1A | |
| SCHEMBL935524 | 0.83 | HIF1A (0.40) | MCL1PTGS2TDP1HIF1A | |
| SCHEMBL8514582 | 0.81 | MCL1 (0.41) | MCL1PTGS2LPAR1S1PR2 | |
| SCHEMBL8515253 | 0.81 | KMT2A (0.51) | MCL1LPAR1ALDH1A1 | |
| SCHEMBL955209 | 0.81 | GCK (0.47) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | claimed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | claimed |
| CN-102471322-A | Pyridone glucokinase activators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | claimed |
| EP-2456767-B1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2456767-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | F. Hoffmann-La Roche AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| CN-102471322-A | Pyridone glucokinase activators | HOFFMANN LA ROCHE | 2012-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131113-A1 | PYRIDONE GLUCOKINASE ACTIVATORS | GCK, PDXK, G6PD | MCL1 4634/4885PPARD 467/4885PPARA 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.